http://lm360.us/Coogan-neighbour-of-Wermers-from-Bundi?Paleaaegr=83 despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6. .eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. . show comments . . all bombay times print stories are available on .